ARTICLE | Distillery Therapeutics
Treating obesity and metabolic syndrome via NR4A2 agonism
May 20, 2019 2:21 PM UTC
INDICATION: Obesity; metabolic syndrome...
BCIQ Company Profiles
BCIQ Target Profiles
Nuclear receptor subfamily 4 group A member 2 (NR4A2) (NURR1)